Tempus Stock
Precision Medicine Solutions
Sign up today and learn more about Tempus Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Tempus Stock
Tempus is a technology-enabled precision medicine solutions company that has built an operating system to battle cancer. It is on a mission to redefine how genomic data is used in a clinical setting. Their goal is for each patient to benefit from the treatment of others who came before by enabling physicians to deliver personalized cancer care for patients through interactive analytical and machine learning platform. Eric Lefkofsky founded it in 2015 and is headquartered in Chicago, Illinois.
Investors
New Enterprise Associates
Robinhood, Databricks, Jet, TAE Technologies, Scopely, Bloom Energy, Opendoor, Radiology Partners, DataRobot, Tempus
T. Rowe Price
One97, Flipkart, WeWork, Cruise, Airbnb, Rivian, Magic Leap, Nuro, Caris Life Sciences, Vroom
Magic Leap, Nuro, Commonwealth Fusion, TAE Technologies, Tempus, Niantic, Symphony Communication Services, Ionic Security, Trifacta, Barefoot Networks
Novo Holdings
Funding History
September 2015 | $10.0M |
---|---|
June 2016 | $10.0M |
November 2016 | $10.0M |
April 2017 | $30.0M |
September 2017 | $70.0M |
March 2018 | $80.0M |
August 2018 | $111M |
April 2019 | $200M |
February 2020 | $97.3M |
November 2020 | $409M |
Management
Chief Executive Officer
Eric Lefkofsky
Chief Financial Officer
Jim Rogers
Chief Technology Officer
Shane Colley
Press
businesswire - Apr, 16 2024
Tempus Introduces its AI-enabled Care Pathway Intelligence Platform, Tempus Nextbusinesswire - Apr, 9 2024
Tempus Introduces Workspaces into its Lens Data Analytics Platformarkansasbusiness - Apr, 5 2024
Tempus Acquires 3 Industrial Properties to Complete $50.9M Portfoliobusinesswire - Mar, 16 2024
Tempus Contributes De-Identified Cancer Data to Planned Data Enclavetheinformation - Mar, 15 2024
Healthcare Startup Tempus Hires Morgan Stanley for IPO